Instituto Butantan responsible for developing the vaccine and conducting trials in the country, announced last week the vaccine had a 78% overall efficacy
Trials in Brazil show the Chinese COVID-19 vaccine Sinovac to be 50.38% effective, nearly 30 percentage points below the initial results released last week. The Instituto Butantan, the São Paulo-based research institute responsible for developing the vaccine and conducting trials in the country, announced last week the vaccine had a 78% overall efficacy, with total protection against severe cases.
The new trials, which involved 12,508 volunteers, have shown that Sinovac continues to be 100% effective in blocking severe cases.
“This is an efficient vaccine,” Instituto Butantan Chief Researcher Ricardo Palacios said during a press conference on Tuesday. “We have a vaccine that is able to control the pandemic through this expected effect, which is the decrease in the disease’s intensity.”